F. Vaylet

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 575 citations

Medicine, Geriatric Medicine, Oncology +10

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

M. Pérol, C. Chouaïd, David Pérol et al. · Journal of Clinical Oncology · 2012 · 233 citations

Medicine, Oncology, Pharmacology +13

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

R. Gervais, A Ducoloné, Jean-Luc Breton et al. · Annals of Oncology · 2004 · 117 citations

Medicine, Oncology, Pharmacotherapy +13

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Charlotte Leduc, J.P. Merlio, Benjamin Besse et al. · Annals of Oncology · 2017 · 93 citations · Full text

Medicine, Molecular Genetics, Oncology +10

A Comparative and Integrative Approach Identifies <i>ATPase Family, AAA Domain Containing 2</i> as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

Robert Fouret, Julien Laffaire, Paul Hofman et al. · Clinical Cancer Research · 2012 · 75 citations

Medicine, Genetics, Oncology +17